Loading
[ 18F]3F4AP / [11C]PIB / Demyelinating Disorders · Phase 1 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 clinical trial registry record for [18F]3F4AP, a novel PET tracer for demyelination imaging, currently recruiting 105 participants across healthy volunteers and six disease groups. No efficacy or safety results are posted; the record documents planned enrollment, study design, and primary outcome measures only.
Phase 1, Interventional, Non Randomized, Single Group, Open label, Diagnostic purpose. Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy; age from 18 Years; to 90 Years; accepts healthy volunteers. Intervention: Alzheimer's Disease (AD); Mild Cognitive Impairment (MCI); Multiple Sclerosis (MS); Spinal Cord Injury (SCI); Spinal radiculopathy (SR). Compared with: Healthy Control — Active Comparator. n = 105. 1 site: United States.
This is a Phase 1 clinical trial registry record for [18F]3F4AP, a novel PET tracer for demyelination imaging, currently recruiting 105 participants across healthy volunteers and six disease groups. No efficacy or safety results are posted; the record documents planned enrollment, study design, and primary outcome measures only.
No safety, tolerability, or pharmacokinetic data are presented in this record.
The source did not state who this applies to in practice.
Phase 1 interventional study of a novel PET tracer in healthy volunteers and disease groups; no results reported in this registry record, only planned enrollment and outcome measures.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06999434). This is a study registration, not published results. Lead sponsor: Yale University. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 105 participants (ESTIMATED). Conditions: Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy. Interventions: DRUG: [ 18F]3F4AP; DRUG: [18F]MK6240; DRUG: [11C]PIB. Primary outcome measures: Tracers volume of distribution (VT) , 5 years; Distribution volume ratio (DVR) , 5 years; Binding potential (BPND) , 5 years; Demyelination , 5 years; Tau burden , 5 years; Amyloid burden , 5 years; Tracer rate constant , 5 years; Associations between imaging modalities and biomarkers. , 5 years. Brief summary: The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.